DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Local Application of Vancomycin Powder in Grade I-IIIA Open Fractures

Information source: University of Tennessee
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Fractures, Open; Surgical Wound Infection

Intervention: Vancomycin (Drug)

Phase: Phase 4

Status: Enrolling by invitation

Sponsored by: University of Tennessee

Official(s) and/or principal investigator(s):
Dirk W Kiner, MD, Principal Investigator, Affiliation: University of Tennessee College of Medicine Chattanooga/Erlanger Health System


The purpose of this study is to determine if local administration of vancomycin powder at the site of Grade I-IIIA open fractures at the time of surgery will be an efficacious method to lower infection rates in open fracture treatment and to elucidate any detrimental effects of applying vancomycin powder at the site of open fractures.

Clinical Details

Official title: Local Application of Vancomycin Powder in Grade I-IIIA Open Fractures

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Primary outcome: Postoperative Infection

Detailed description: Hypothesis: Local administration of 1 gram of vancomycin powder at the site of primarily closeable Gustilo-Anderson Grade I-IIIA open fractures at the time of surgery, in addition to clinically accepted open fracture management (intravenous antibiotics, surgical irrigation and debridement and stabilization), will significantly decrease the postoperative infection rate in comparison to the current treatment algorithm. Methods: Study subjects will be randomized to one of two groups prior to surgery (parallel group design): standard treatment (control group) versus vancomycin powder treatment (experimental group). Each group will have an equal number of subjects. Once randomized, the intervention is then un-blinded to facilitate treatment. Post-operatively, all patients will receive intravenous antibiotics, such that all patients receive a total of 24 hours of intravenous antibiotics. The surgical drain will be removed at the patient's bedside approximately 24 hours after the surgical procedure. Patients will follow up with their surgeon for routine scheduled visits at approximately 2 weeks, 6 weeks, 12 weeks, and further until aseptic union or resolution of infection. There will be no additional appointments solely for the purpose of research follow-up.


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Skeletally mature patients ≥18 years of age

- Acute Gustilo-Anderson Type I-IIIA open fracture

- Fracture is deemed primarily closable at initial surgery

- Likely to follow-up with surgeon until fracture is healed

- Ability to understand and agree to Informed Consent

Exclusion Criteria:

- Patients <18 years of age

- Gustilo-Anderson Type IIIB and IIIC open fractures

- Open fractures requiring multiple operations (i. e. for repeat surgical debridement or

staged bone grafting of critical segmental defects)

- Delayed presentation of open fracture

- Pre-existing systemic infection requiring antibiotic therapy

- Allergy to Vancomycin

- Open fracture at the site of a previous fracture or surgical site

- Current skin infection, chronic wounds or known systemic infection

- Unlikely to follow-up until fracture is healed

- Unable to understand or agree to Informed Consent

Locations and Contacts

Erlanger Health System, Chattanooga, Tennessee 37403, United States
Additional Information

Starting date: March 2015
Last updated: March 23, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017